Moleculin Biotech, Inc. is preclinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology.

Investor Relations

Latest Financial Results

Q1 2017

Quarter Ended Mar 31, 2017

Stock Information

NASDAQ

MBRX

Price

Change

Volume

52 week Low/High

Day Low/High

Company Overview

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Our lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. We also have two active pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient's own immune system. The other portfolio targets the metabolism of tumors.

Contact Information

Investor Relations
PCG Advisory
Kirin M. Smith
Chief Operating Officer
T: (646) 863-6519

Transfer Agent
VStock Transfer, LLC

Auditor
Grant Thornton LLP

Legal Counsel
Schiff Hardin LLP
Cavas Pavri